To prevent false positive calls caused by CHIP mutations, which can be mistaken as tumor-specific mutations present in post-treatment plasma under rare circumstances, sequencing the matching WBC sample when a plasma sample is marginally called MRD positive may be beneficial. This evidence concerns the gene STUB1 and neoplasm.